Temporal Quantitative Proteomics Analysis of Neuroblastoma Cells Treated with Bovine Milk-Derived Extracellular Vesicles Highlights the Anti-Proliferative Properties of Milk-Derived Extracellular Vesicles.
Animals
Cattle
Cell Line, Tumor
Cell Proliferation
Cellular Senescence
Doxorubicin
/ pharmacology
Extracellular Vesicles
/ metabolism
Gene Expression Regulation, Neoplastic
/ drug effects
Milk
/ chemistry
N-Myc Proto-Oncogene Protein
/ metabolism
Neoplasm Invasiveness
Neoplasm Proteins
/ metabolism
Neuroblastoma
/ genetics
Proteomics
N-Myc
bovine milk-derived extracellular vesicles chemotherapy
extracellular vesicles
neuroblastoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
29 03 2021
29 03 2021
Historique:
received:
24
02
2021
revised:
23
03
2021
accepted:
25
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Neuroblastoma (NBL) is a pediatric cancer that accounts for 15% of childhood cancer mortality. Amplification of the oncogene N-Myc occurs in 20% of NBL patients and is considered high risk as it correlates with aggressiveness, treatment resistance and poor prognosis. Even though the treatment strategies have improved in the recent years, the survival rate of high-risk NBL patients remain poor. Hence, it is crucial to explore new therapeutic avenues to sensitise NBL. Recently, bovine milk-derived extracellular vesicles (MEVs) have been proposed to contain anti-cancer properties. However, the impact of MEVs on NBL cells is not understood. In this study, we characterised MEVs using Western blotting, NTA and TEM. Importantly, treatment of NBL cells with MEVs decreased the proliferation and increased the sensitivity of NBL cells to doxorubicin. Temporal label-free quantitative proteomics of NBL cells highlighted the depletion of proteins involved in cell metabolism, cell growth and Wnt signalling upon treatment with MEVs. Furthermore, proteins implicated in cellular senescence and apoptosis were enriched in NBL cells treated with MEVs. For the first time, this study highlights the temporal proteomic profile that occurs in cancer cells upon MEVs treatment.
Identifiants
pubmed: 33805332
pii: cells10040750
doi: 10.3390/cells10040750
pmc: PMC8065825
pii:
doi:
Substances chimiques
MYCN protein, human
0
N-Myc Proto-Oncogene Protein
0
Neoplasm Proteins
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Trends Cell Biol. 2017 Mar;27(3):172-188
pubmed: 27979573
Nucleic Acids Res. 2007 Jan;35(Database issue):D61-5
pubmed: 17130148
J Extracell Vesicles. 2018 Feb 21;7(1):1440132
pubmed: 29511463
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
J Neurooncol. 2013 May;113(1):1-11
pubmed: 23456661
J Dairy Sci. 2012 Sep;95(9):4831-4841
pubmed: 22916887
Nutrients. 2016 May 11;8(5):
pubmed: 27187450
J Nutr. 2016 Nov;146(11):2206-2215
pubmed: 27708120
Sci Rep. 2017 Jul 19;7(1):5933
pubmed: 28725021
J Extracell Vesicles. 2017 May 26;6(1):1321455
pubmed: 28717418
Cell Adh Migr. 2017 Jan 2;11(1):68-79
pubmed: 27224546
Cell Physiol Biochem. 2014;33(2):402-12
pubmed: 24556602
J Cell Sci. 2019 Apr 26;132(8):
pubmed: 30872458
Cold Spring Harb Perspect Med. 2013 Oct 01;3(10):a014415
pubmed: 24086065
Proteomics. 2013 Nov;13(22):3354-64
pubmed: 24115447
J Extracell Vesicles. 2019 Nov 15;8(1):1690217
pubmed: 31819794
Oncogene. 2013 Jan 17;32(3):307-17
pubmed: 22370639
Elife. 2016 Mar 07;5:e13722
pubmed: 26949251
Proteomics. 2015 Aug;15(15):2597-601
pubmed: 25921073
Proc Natl Acad Sci U S A. 2016 May 31;113(22):6254-8
pubmed: 27185926
Cell Rep. 2018 Jan 16;22(3):748-759
pubmed: 29346771
PLoS One. 2017 Jan 12;12(1):e0169934
pubmed: 28081261
PLoS One. 2019 Jan 30;14(1):e0211431
pubmed: 30699187
Genes Dev. 2006 Mar 1;20(5):586-600
pubmed: 16510874
Int J Oncol. 2008 Oct;33(4):815-21
pubmed: 18813796
J Mol Biol. 2020 Dec 11;:166747
pubmed: 33310018
Cancer Lett. 2017 May 1;393:94-102
pubmed: 28202351
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1229-E1238
pubmed: 29374092
J Extracell Vesicles. 2019 Apr 11;8(1):1597614
pubmed: 31007876
J Dairy Sci. 2015 May;98(5):2920-33
pubmed: 25726110
Oncol Rep. 2018 Jul;40(1):355-360
pubmed: 29749541
Methods. 2011 Aug;54(4):396-406
pubmed: 21272644
Pediatr Rev. 2018 Apr;39(4):194-203
pubmed: 29610427
Oncol Lett. 2018 Aug;16(2):1835-1840
pubmed: 30008873
Stem Cell Investig. 2017 Sep 12;4:74
pubmed: 29057246
Epigenetics. 2016 Oct 2;11(10):721-729
pubmed: 27494402
J Extracell Vesicles. 2017 Nov 21;6(1):1401897
pubmed: 29904572
Curr Opin Clin Nutr Metab Care. 2018 May;21(3):200-206
pubmed: 29461264
Oncologist. 2003;8(3):278-92
pubmed: 12773750
Cell Death Dis. 2019 Nov 4;10(11):835
pubmed: 31685805
Cell Mol Life Sci. 2014 Feb;71(3):517-38
pubmed: 23807208
Sci Rep. 2018 Jul 27;8(1):11321
pubmed: 30054561
Bioscience. 2015 Aug 1;65(8):783-797
pubmed: 26955082
Int J Mol Sci. 2016 Feb 06;17(2):170
pubmed: 26861301
J Immunol. 2007 Aug 1;179(3):1969-78
pubmed: 17641064
PLoS One. 2017 Aug 29;12(8):e0183915
pubmed: 28850588
Food Funct. 2017 Nov 15;8(11):4100-4107
pubmed: 28991298
J Transl Med. 2019 Dec 26;17(1):428
pubmed: 31878941
J Cell Sci. 2010 May 15;123(Pt 10):1603-11
pubmed: 20445011
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
Commun Biol. 2019 Aug 9;2:305
pubmed: 31428693
Int J Biol Sci. 2018 Apr 30;14(6):633-643
pubmed: 29904278
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
J Clin Oncol. 2000 Jan;18(1):18-26
pubmed: 10623689
Proteomes. 2020 May 13;8(2):
pubmed: 32414045
Clin Cancer Res. 2019 Jul 1;25(13):4063-4078
pubmed: 30952635
J Clin Oncol. 1999 Jul;17(7):2264-79
pubmed: 10561284
Biochim Biophys Acta Proteins Proteom. 2019 Dec;1867(12):140203
pubmed: 30822540
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Oncotarget. 2015 May 10;6(13):11175-90
pubmed: 25883214
Crit Rev Oncol Hematol. 2016 Nov;107:163-181
pubmed: 27823645